| ［1］ |
De Giorgi V, Colombo J, Salvati L, et al. Eruptive halo nevi: a new COVID⁃19 vaccine⁃related cutaneous adverse event or a paraneoplastic phenomenon?［J］. Dermatol Ther, 2022,35（9）:e15722. doi: 10.1111/dth.15722.
|
| ［2］ |
Jia WX, Zhang YY, Li CR. Four⁃color halo congenital nevus［J］. J Cosmet Dermatol, 2021,20（11）:3712⁃3713. doi: 10.1111/jocd.14056.
|
| ［3］ |
Babu A, Bhat MR, Dandeli S, et al. Throwing light onto the core of a halo nevus: a new finding［J］. Indian J Dermatol, 2016,61（2）:238. doi: 10.4103/0019⁃5154.177801.
|
| ［4］ |
Hassab⁃El⁃Naby H, Rageh MA. Agminated halo nevus: a novel presentation［J］. Am J Dermatopathol, 2023,45（6）:388⁃390. doi: 10.1097/DAD.0000000000002417.
|
| ［5］ |
Rongioletti F, Cecchi F, Rebora A. Halo phenomenon in melanocytic nevi（Sutton′s nevi）. Does the diameter matter?［J］. J Eur Acad Dermatol Venereol, 2011,25（10）:1231⁃1232. doi: 10.1111/j.1468⁃3083.2010.03790.x.
|
| ［6］ |
Haynes D, Strunck JL, Said J, et al. Association between halo nevi and melanoma in adults: a multicenter retrospective case series［J］. J Am Acad Dermatol, 2021,84（4）:1164⁃1166. doi: 10.1016/j.jaad.2020.08.056.
|
| ［7］ |
Yamazaki E, Irimada M, Sasaki R, et al. Multiple halo nevi associated with Turner syndrome［J］. J Dermatol, 2021,48（1）:e11⁃e12. doi: 10.1111/1346⁃8138.15643.
|
| ［8］ |
黄新绿, 杜娟, 徐前喜, 等. 晕痣的流行病学调查、临床特征及皮肤镜表现［J］. 中国皮肤性病学杂志, 2021,35（12）:1371⁃1376.doi:10.13735/j.cjdv.1001⁃7089.202106084
|
| ［9］ |
Pogorzelska⁃Antkowiak A, Corneli P, Agozzino M. In vivo reflectance confocal microscopy of halo nevi［J］. Skin Res Technol, 2021,27（5）:841⁃845. doi: 10.1111/srt.13029.
|
| ［10］ |
Pan C, Shang J, Jiang H, et al. Transcriptome analysis reveals the molecular immunological characteristics of lesions in patients with halo nevi when compared to stable vitiligo, normal nevocytic nevi and cutaneous melanoma［J］. J Inflamm Res, 2021,14:4111⁃4124. doi: 10.2147/JIR.S321672.
|
| ［11］ |
Kumar Jha A, Sonthalia S, Lallas A, et al. Dermoscopy in vitiligo: diagnosis and beyond［J］. Int J Dermatol, 2018,57（1）:50⁃54. doi: 10.1111/ijd.13795.
|
| ［12］ |
Gupta P, Vinay K, Bishnoi A, et al. A prospective observational study to sequentially determine the dermoscopic features of vitiligo and its association with disease activity in patients on medical treatment: dermoscopy and disease activity in vitiligo［J］. Pigment Cell Melanoma Res, 2023,36（1）:33⁃41. doi: 10. 1111/pcmr.13069.
|
| ［13］ |
胡文婷, 许爱娥. 晕痣的研究进展［J］. 中国皮肤性病学杂志,2017,31（7）:800⁃802. doi: 10.13735/j.cjdv.1001⁃7089.201607001.
|
| ［14］ |
金城, 陆洪光, 赵志国, 等. 晕痣的免疫组化特点与自发性消退机制的研究［J］. 中华皮肤科杂志, 2008,41（4）:237⁃240.doi:10.3321/j.issn:0412⁃4030.2008.04.009
|
| ［15］ |
George EV, Kalen JE, Kapil JP, et al. Comparison of the inflammatory infiltrates in tumoral melanosis, regressing nevi, and regressing melanoma［J］. Am J Dermatopathol, 2019,41（7）:480⁃487. doi: 10.1097/DAD.0000000000001346.
|
| ［16］ |
Park HS, Jin SA, Choi YD, et al. Foxp3（+） regulatory T cells are increased in the early stages of halo nevi: clinicopathological features of 30 halo nevi［J］. Dermatology, 2012,225（2）:172⁃178. doi: 10.1159/000342757.
|
| ［17］ |
Kano S, Nakamura M, Nojiri Y, et al. Differences in the immune microenvironment between improved and non⁃improved cases of vitiligo after halo nevus excision［J］. J Dermatol Sci, 2023,109（3）:136⁃142. doi: 10.1016/j.jdermsci.2023.03.004.
|
| ［18］ |
Yang Y, Li S, Zhu G, et al. A similar local immune and oxidative stress phenotype in vitiligo and halo nevus［J］. J Dermatol Sci, 2017,87（1）:50⁃59. doi: 10.1016/j.jdermsci.2017.03.008.
|
| ［19］ |
Lin F, Hu W, Xu W, et al. CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation［J］. Sci Rep, 2021,11（1）:18298. doi: 10.1038/s41598⁃021⁃97296⁃2.
|
| ［20］ |
Lorentzen HF. Eruptive halo naevi: a possible indicator of malignant disease in a case series of post⁃adolescent patients［J］. Acta Derm Venereol, 2020,100（15）:adv00228. doi: 10.2340/ 00015555⁃3568.
|
| ［21］ |
Emre S, Süngü N, Hayran Y, et al. Investigation of the PD⁃1/PD⁃L1 expression in the lesional skins of patients with psoriasis［J］. Dermatol Pract Concept, 2023,13（2）:e2023134. doi: 10.5826/ dpc.1302a134.
|
| ［22］ |
Tan CL, Kuchroo JR, Sage PT, et al. PD⁃1 restraint of regulatory T cell suppressive activity is critical for immune tolerance［J］. J Exp Med, 2021,218（1）:e20182232. doi: 10.1084/jem.20182232.
|
| ［23］ |
曹伟, 冯玉婷, 王小媛, 等. 寻常型白癜风与晕痣患者外周血T淋巴细胞亚群及Th1/Th2、Th17/Treg细胞平衡比较［J］. 实用临床医药杂志, 2020,24（12）:84⁃86. doi: 10.7619/jcmp.2020 12024.
|
| ［24］ |
Halliday GM, Patel A, Hunt MJ, et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells［J］. World J Surg, 1995,19（3）:352⁃358. doi: 10.1007/BF00299157.
|
| ［25］ |
Schiferle EB, Cheon SY, Ham S, et al. Rejection of benign melanocytic nevi by nevus⁃resident CD4（+） T cells［J］. Sci Adv, 2021,7（26）:eabg4498. doi: 10.1126/sciadv.abg4498.
|
| ［26］ |
Fernández⁃Herrera J, Fernández⁃Ruiz E, López⁃Cabrera M, et al. CD69 expression and tumour necrosis factor⁃alpha immunoreactivity in the inflammatory cell infiltrate of halo naevi［J］. Br J Dermatol, 1996,134（3）:388⁃393.
|
| ［27］ |
Farinazzo E, Zelin E, Agozzino M, et al. Regression of nevi, vitiligo⁃like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma［J］. Melanoma Res, 2021,31（6）:582⁃585. doi: 10.1097/CMR.000 0000000000776.
|
| ［28］ |
Ding GZ, Zhao WE, Li X, et al. A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin［J］. Arch Dermatol Res, 2015,307（3）:281⁃289. doi: 10.1007/s00403⁃015⁃1544⁃4.
|
| ［29］ |
Beyer AM, Norwood Toro LE, Hughes WE, et al. Autophagy, TERT, and mitochondrial dysfunction in hyperoxia［J］. Am J Physiol Heart Circ Physiol, 2021,321（5）:H985⁃H1003. doi: 10. 1152/ajpheart.00166.2021.
|
| ［30］ |
Varga G, Gattorno M, Foell D, et al. Redox distress and genetic defects conspire in systemic autoinflammatory diseases［J］. Nat Rev Rheumatol, 2015,11（11）:670⁃680. doi: 10.1038/nrrheum. 2015.105.
|
| ［31］ |
Seneschal J, Boniface K, D′Arino A, et al. An update on Vitiligo pathogenesis［J］. Pigment Cell Melanoma Res, 2021,34（2）:236⁃243. doi: 10.1111/pcmr.12949.
|
| ［32］ |
胡文婷, 黄骏, 许爱娥. 不同治疗方法对晕痣疗效的影响因素分析［J］. 中华皮肤科杂志, 2018,51（2）:121⁃125. doi: 10.3760/cma.j.issn.0412⁃4030.2018.02.008.
|
| ［33］ |
Wang K, Wang Z, Huang W. Resolution of vitiligo following excision of halo congenital melanocytic nevus: a rare case report［J］. Dermatol Ther, 2016,29（3）:145⁃147. doi: 10.1111/dth.12326.
|
| ［34］ |
Hu WT, Lin FQ, Xu AE. Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5［J］. Clin Exp Dermatol, 2018,43（8）:935⁃937. doi: 10.1111/ced.13672.
|
| ［35］ |
Abdel Aziz RTA, Awad SS, Mohammed SS. Effectiveness and safety of Chinese cups in the treatment of halo nevi［J］. Dermatol Surg, 2021,47（1）:150⁃151. doi: 10.1097/DSS.0000000000002288.
|
